Just eight months after it introduced its oral version of semaglutide for obesity, also known as the Wegovy pill, Novo ...

If at first you don’t succeed in gene therapy, then try, try again. | If at first you don’t succeed in gene therapy, then try ...

China's investigator-initiated trials, once praised for their speediness, have been drawn into scrutiny for a lack of ...

For patients living with Type 2 diabetes in the United Kingdom, a more convenient treatment option may be on the horizon ...

After more than 10 years in development, Regeneron secured a landmark approval for its monoclonal antibody garetosmab, now ...

Eight months after more than doubling down on its construction of a $2 billion drug manufacturing facility in Holly Springs, ...

Aurinia Pharmaceuticals has struck a patent infringement settlement with Teva Pharmaceuticals, which should help stave off ...

Less than a year after the FDA turned down the resubmitted application for the company’s leukemia prospect Dasynoc, Xspray ...

B. Braun Medical—a maker of IV solutions for hospitals, among other products—has initiated a recall in the United States and ...

SK’s deal with India’s MSN Laboratories will allow the Korean company to extend its market exclusivity beyond October of 2032 ...

Almost three years into his tenure as Lundbeck’s CEO, Charl van Zyl is confident the company can prove its mettle as a ...

After receiving a checkered regulatory scorecard in 2024, Aurobindo’s sterile injectables and oncology unit is back in the ...